Linxiang Q. Zhao

103 Wenhua Road
Shengyang, 110016, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

Fluorescence Polarization-Based High-Throughput Screening Enables Identification of Vibrio β-Lactam Resistance Sensor Kinase Inhibitors to Counteract Antibiotic Resistance.

Fluorescence Polarization-Based High-Throughput Screening Enables Identification of Vibrio β-Lactam Resistance Sensor Kinase Inhibitors to Counteract Antibiotic Resistance.

Journal: Journal of medicinal chemistry
Published: April 30, 2026

Optimization of 4-Aniline Substituted Pyrido[3,2-d]pyrimidine Derivatives as Pim/Mnk Dual Inhibitors with Antileukemia Activity.

Optimization of 4-Aniline Substituted Pyrido[3,2-d]pyrimidine Derivatives as Pim/Mnk Dual Inhibitors with Antileukemia Activity.

Journal: Journal of medicinal chemistry
Published: March 24, 2026

Discovery of a Covalent HDAC3 Degrader with Excellent Anti-Inflammatory Activity and NLRP3 Inflammasome Suppression.

Discovery of a Covalent HDAC3 Degrader with Excellent Anti-Inflammatory Activity and NLRP3 Inflammasome Suppression.

Journal: Journal of medicinal chemistry
Published: March 11, 2026

Design, Synthesis, and Biological Evaluation of a Series of Novel LFA-1 Antagonists with Enhanced Potency and Ocular Safety for Dry Eye Disease.

Design, Synthesis, and Biological Evaluation of a Series of Novel LFA-1 Antagonists with Enhanced Potency and Ocular Safety for Dry Eye Disease.

Journal: Journal of medicinal chemistry
Published: December 23, 2025

Corrigendum to "Thiol esters as chemical warheads of SARS-CoV-2 main protease (3CLpro) peptide-like inhibitors" [Eur. J. Med. Chem. 293 (2025) 117709].

Corrigendum to "Thiol esters as chemical warheads of SARS-CoV-2 main protease (3CLpro) peptide-like inhibitors" [Eur. J. Med. Chem. 293 (2025) 117709].

Journal: European journal of medicinal chemistry
Published: December 10, 2025

Discovery of TNI-97 as a Highly Selective, Orally Bioavailable HDAC6 Inhibitor for the Treatment of Triple-Negative Breast Cancer.

Discovery of TNI-97 as a Highly Selective, Orally Bioavailable HDAC6 Inhibitor for the Treatment of Triple-Negative Breast Cancer.

Journal: Journal of medicinal chemistry
Published: July 03, 2025

Thiol esters as chemical warheads of SARS-CoV-2 main protease (3CLpro) peptide-like inhibitors.

Thiol esters as chemical warheads of SARS-CoV-2 main protease (3CLpro) peptide-like inhibitors.

Journal: European journal of medicinal chemistry
Published: January 21, 2025

Overcoming venetoclax resistance through heme-mediated NOXA/cyclin D1/Mcl-1 axis with a novel artemisinin conjugate.

Overcoming venetoclax resistance through heme-mediated NOXA/cyclin D1/Mcl-1 axis with a novel artemisinin conjugate.

Journal: Blood advances
Published: January 03, 2025

Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors.

Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors.

Journal: Journal of medicinal chemistry
Published: November 27, 2024

Discovery of 4,5-dihydro-benzo[g]indazole-based hydroxamic acids as HDAC3/BRD4 dual inhibitors and anti-tumor agents.

Discovery of 4,5-dihydro-benzo[g]indazole-based hydroxamic acids as HDAC3/BRD4 dual inhibitors and anti-tumor agents.

Journal: European journal of medicinal chemistry
Published: November 19, 2024

Discovery of Novel Mcl-1 Inhibitors with a 3-Substituted-1H-indole-1-yl Moiety Binding to the P1-P3 Pockets to Induce Apoptosis in Acute Myeloid Leukemia Cells.

Discovery of Novel Mcl-1 Inhibitors with a 3-Substituted-1H-indole-1-yl Moiety Binding to the P1-P3 Pockets to Induce Apoptosis in Acute Myeloid Leukemia Cells.

Journal: Journal of medicinal chemistry
Published: August 09, 2024

Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.

Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.

Journal: Journal of medicinal chemistry
Published: April 10, 2024
Showing 1-12 of 37

Last Updated: 09/26/2026